MenopauseWOMEN-EX-MODNCT06533982
Effect of Different Exercise Modalities on Cardiovascular and Cognitive Response in Postmenopausal Women
A study testing High intensity interval exercise session and Isometric neuromuscular exercise session in people with Menopause and Blood Pressure, run by University of Poitiers at 1 site in France.
Trial summary
Menopause is a natural stage in female aging, increasing cardiometabolic risk and making cardio-neuro-vascular disease (CNVD) the leading cause of mortality in women over 60. Declining ovarian hormones are linked to changes in body composition, increased blood pressure, and mild cognitive impairment. Read more about this study
- Who is it for?
- Ages 45 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Menopause, Blood Pressure, Cognitive Decline
- What is being tested?
- High intensity interval exercise session and Isometric neuromuscular exercise session
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- 10 Mar 2023to 20 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Menopausal women (absence of menstruation for 12 consecutive months) for less than 10 years
- Women with or without vasomotor symptoms
- Women covered by the French Social Security system
Who cannot join
- Surgical menopause (oophorectomy)
- Premature ovarian failure
- Chronic renal failure
- Respiratory pathology (unstable asthma, respiratory insufficiency or pulmonary hypertension)
- Cardiovascular disease (coronary, valvular, hypertrophic, hypertensive, infiltrative, constrictive or rhythmic)
- Medically treated hypertension
Show all 11Show fewer
- Severe obesity (BMI > 40 kg/m²)
- Hearing or vision problems that prevent reading or distinguishing colors
- Recent (< 1 year) central neurological or psychiatric disorders
- Moderate to severe cognitive impairment (MoCA < 18).
- Judicial protection or guardianship
Trial locations and contacts
1 site in 1 country.
France1 site
Faculty of Sport Science - MOVE Laboratory (UR20296)
Poitiers, 86000
About this study
Official title: Effect of Different Exercise Modalities on Cardiovascular and Cognitive Response in Postmenopausal Women With and Without Vasomotor Symptoms
Menopause is a natural stage in female aging, increasing cardiometabolic risk and making cardio-neuro-vascular disease (CNVD) the leading cause of mortality in women over 60. Declining ovarian hormones are linked to changes in body composition, increased blood pressure, and mild cognitive impairment. Menopause also often involves significant symptoms like menopausal vasomotor symptoms (VMS), affecting 60-80% of women for 5-10 years. Women with VMS exhibit a worse cardiovascular profile and greater cognitive decline.
Physical exercise is a promising non-pharmacological option to reduce CNVD risk and limit cognitive impairment in postmenopausal women, who have a 10-year window post-menopause during which physical activity benefits vascular and possibly neurovascular health. Studies link physical activity to lower cognitive decline and improved quality of life. However, optimal exercise modalities for managing CNVD risk in postmenopausal women remain undetermined.
Read the detailed description
Menopause is a natural stage in the female aging process, resulting in increased cardiometabolic risk, making cardio-neuro-vascular disease (CNVD) the leading cause of female mortality worldwide after the age of 60. Indeed, falling ovarian hormone concentrations are associated with altered body composition, increased blood pressure, as well as mild cognitive impairment.
For some women, menopause is also accompanied by symptoms that have a significant impact on their quality of life. Among these, menopausal vasomotor symptoms (VMS - hot flushes, night sweats...) are the most frequent, affecting 60% to 80% of women for an average of 5 to 10 years. Several studies have highlighted an altered cardiovascular profile (dyslipidemia, insulin resistance, pre-hypertension/hypertension...) and a more marked decline in cognitive performance in women with VMS.
In order to reduce the risk of CNVD and limit cognitive impairment, physical exercise appears to be a particularly interesting non-pharmacological management option for postmenopausal women. Indeed, the latter seem to present a 10-year post-menopausal time window, during which physical activity has a positive vascular and probably neurovascular effect, although the latter remains to be demonstrated. Numerous studies have also shown that physical activity is associated with a lower rate of cognitive decline, and improved quality of life.
However, to date, there is little evidence to determine which exercise modalities are most effective in managing the risk of CNVD in postmenopausal women.
The aims of this study:
- To examine the effect of exercise on markers of cardio-neuro-vascular health and cognition in postmenopausal women.
- Second, to compare the differences in the cardio-neuro-vascular and cognitive response to exercise, dependent on the type of exercise, the physical fitness and the presence of menopausal symptoms.
- Third, to examine the effect of menopausal symptoms, and physical fitness on cardio-neuro-vascular health markers and cognitive health markers.
- Conditions
- Menopause, Blood Pressure, Cognitive Decline
- Being tested
- High intensity interval exercise session, Isometric neuromuscular exercise session
- Keywords
- Physical exercise, High intensity interval exercise, Handgrip
- Medical subject headings
- Cognitive Dysfunction, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High intensity interval exercise sessionOther
Physical activity session supervised and adapted on ergometer
Isometric neuromuscular exercise sessionOther
Physical activity session supervised and adapted with a handgrip
| Study group | Role | What they receive |
|---|---|---|
| High intensity interval exercise session | Experimental | Performed on an ergometer, the intensity of the session is adapted to the participant's physical capacity, initially assessed by the VO2max test at baseline.
The session begins with a 5-minute warm-up at 50% of maximum aerobic power (MAP). The exercise then consists of 2 sets of 12 repetitions of 15 seconds each at 100% of MAP and 15 seconds of passive recovery. 2-minute of passive recovery is recommended between the two sets. The session ends with 5-minute of recovery at 50% of MAP. Receives: Other: High intensity interval exercise session |
| Isometric neuromuscular exercise session | Experimental | Performed with a handgrip (K-Force grip, KINVENT), the intensity of the session is adapted to the participant's capacity, initially assessed by the isometric maximal voluntary force (MVF) measurement at the beginning of the session.
The session consists of 4 repetitions of 2 minutes at 30% of the isometric MVF, separated by 1 minute recovery. Receives: Other: Isometric neuromuscular exercise session |
| Control session | No intervention | Participants are seated for 30 minutes. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic and diastolic blood pressure (ambulatory blood pressure measurement)
Post-exercise hypotension, using the Mobil-O-Graph (mmHg).
Measured: After sessions (24 hours)
Systolic and diastolic blood pressure (resting)
Automated oscillometric tensiometer (mmHg).
Measured: Before and after sessions (15 minutes)
Secondary outcomes (25)
Concentration of cerebral oxygenation
Near-infrared spectroscopy is used to measure concentrations of oxygenated and desoxygenated hemoglobin (µmol/L).
Measured: Before, during, and after sessions (1 hour)
Working memory
2-back task (scored from 0 to 28, higher scores indicate better working memory).
Measured: Before and after sessions (10 minutes)
Episodic memory
Memory scale III (MEM-III), a story recall task taken from the test battery in the Wechsler-Memory Scale-Revised (scored from 0 to 25, higher scores indicate better episodic memory).
Measured: Before and after sessions (15 minutes)
Executive function
Stroop task, used to assess inhibitory control (scored as a ratio, negative score indicates worse inhibitory control vs. positive score indicates better inhibitory control).
Measured: Before and after sessions (15 minutes)
Perception of exertion
Modified Borg scale (scored 0 to 10, higher score indicates lower exercise tolerance).
Measured: After sessions (1 minute)
Endothelial function (brachial artery dilation capacity)
At rest, the flow-mediated dilatation technique is used with high-resolution Doppler ultrasound (CX-50 Philipps).
Measured: Baseline (30 minutes)
Baroreflex sensitivity
At rest, baroreflex sensitivity is measured using the Finapres.
Measured: Baseline (1 hour)
Aortic systolic and diastolic blood pressure
At rest, using the SphygmoCor device, which measures central blood pressure (mmHg).
Measured: Baseline (15 minutes)
Arterial stiffness (pulse wave velocity)
At rest, using the SphygmoCor device, which calculates carotid-femoral pulse wave velocity (m/s).
Measured: Baseline (15 minutes)
Physical fitness
Maximal cardiopulmonary effort test (VO2max).
Measured: Baseline (30 minutes)
Blood lipid concentrations
Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (g/L).
Measured: Baseline (5 minutes)
Blood hormone concentrations
Progesterone, 17-beta-estradiol, and follicle-stimulating hormone (ng/L).
Measured: Baseline (5 minutes)
Body weight
Total body weight, fat mass, fat-free mass and visceral-fat mass in kilograms using the Tanita impedance scale.
Measured: Baseline (1 minute)
Body composition
Percentage of body fat and fat-free mass using the Tanita impedance scale.
Measured: Baseline (1 minute)
Height
Height in meters measured with a height gauge.
Measured: Baseline (1 minute)
Body mass index
Calculated from total body weight and height (kg/m²).
Measured: Baseline (1 minute)
Cognitive assessment
Montreal Cognitive Assessment (MoCA) test (scored from 0 to 30, with higher scores indicating better cognitive function).
Measured: Baseline (15 minutes)
Menopausal rating scale
Composed of 11 items rating the severity of menopausal symptoms from 0 (no symptoms) to 4 (very severe).
Measured: Baseline (15 minutes)
Hot flash related daily interference scale
Composed of 10 items scored from 0 (no impact) to 10 (completely interferes), evaluating the impact of vasomotor symptoms on daily life.
Measured: Baseline (15 minutes)
Hospital Anxiety and Depression Scale
It provides two scores ranging from 0 to 21 that quantify anxiety and depression. Higher scores indicate more severe symptoms.
Measured: Baseline (15 minutes)
Global physical activity questionnaire
Physical activity and sedentary time assessed using the Global Physical Activity Questionnaire. Higher scores indicate better physical activity levels (categorized into high, moderate, and low physical activity levels).
Measured: Baseline (15 minutes)
Daily tobacco and alcohol use
Use daily or not use.
Measured: Baseline
Age
Age, age at menarche and menopause (in years).
Measured: Baseline
Educational level
Secondary education, high school graduate, bachelor's degree, master's or doctoral degree.
Measured: Baseline
Number of children
Self-reported.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2024
- Study start10 Mar 2023
- Primary completion28 Mar 2023
- Study completion20 Dec 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for MenopauseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Poitiers
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Laurent Bosquet, University of Poitiers
- Investigators
- Laurent Bosquet, Pr, Principal investigator, University of Poitiers - Faculty of Sport Science - MOVE Laboratory (UR20296)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06533982
- Sponsor's protocol ID
- WOMEN-EX-MOD
- Acronym
- WOMEN-EX-MOD
- Status last verified
- Jul 2024
- First submitted
- 19 Jul 2024
- Last updated
- 1 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Armas Rojas N, Dobell E, Lacey B, Varona-Perez P, Burrett JA, Lorenzo-Vazquez E, Calderon Martinez M, Sherliker P, Bess Constanten S, Morales Rigau JM, Hernandez Lopez OJ, Martinez Morales MA, Alonso Aloma I, Achiong Estupinan F, Diaz Gonzalez M, Rosquete Munoz N, Cendra Asencio M, Peto R, Emberson J, Duenas Herrera A, Lewington S. Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study. Lancet Public Health. 2019 Feb;4(2):e107-e115. doi: 10.1016/S2468-2667(18)30210-X. Epub 2019 Jan 23.
PubMed 30683584Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, Cauley JA, Finkelstein JS, Jiang SF, Karlamangla AS. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 Mar 7;4(5):e124865. doi: 10.1172/jci.insight.124865. eCollection 2019 Mar 7.
PubMed 30843880Boyle CP, Raji CA, Erickson KI, Lopez OL, Becker JT, Gach HM, Kuller LH, Longstreth W Jr, Carmichael OT, Riedel BC, Thompson PM. Estrogen, brain structure, and cognition in postmenopausal women. Hum Brain Mapp. 2021 Jan;42(1):24-35. doi: 10.1002/hbm.25200. Epub 2020 Sep 10.
PubMed 32910516Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063.
PubMed 25686030Zhu D, Chung HF, Dobson AJ, Pandeya N, Anderson DJ, Kuh D, Hardy R, Brunner EJ, Avis NE, Gold EB, El Khoudary SR, Crawford SL, Mishra GD. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol. 2020 Dec;223(6):898.e1-898.e16. doi: 10.1016/j.ajog.2020.06.039. Epub 2020 Jun 23.
PubMed 32585222Gliemann L, Hellsten Y. The exercise timing hypothesis: can exercise training compensate for the reduction in blood vessel function after menopause if timed right? J Physiol. 2019 Oct;597(19):4915-4925. doi: 10.1113/JP277056. Epub 2019 Jun 30.
PubMed 31077368Anderson D, Seib C, Rasmussen L. Can physical activity prevent physical and cognitive decline in postmenopausal women? A systematic review of the literature. Maturitas. 2014 Sep;79(1):14-33. doi: 10.1016/j.maturitas.2014.06.010. Epub 2014 Jun 20.
PubMed 25008420Hybholt M. Psychological and social health outcomes of physical activity around menopause: A scoping review of research. Maturitas. 2022 Oct;164:88-97. doi: 10.1016/j.maturitas.2022.07.014. Epub 2022 Aug 3.
PubMed 35964395Bourvellec ML, Delpech N, Sosner P, Fritel X, Bosquet L, Enea C. Effect of Exercise Modalities on Post-Exercise Hypotension in Normotensive Postmenopausal Women: A Randomized Controlled Trial on Vasomotor Symptoms Influence. Eur J Sport Sci. 2025 Dec;25(12):e70091. doi: 10.1002/ejsc.70091.
PubMed 41273313
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Different Exercise Modalities on Cardiovascular and Cognitive Response in Postmenopausal Women With and Without Vasomotor Symptoms
- ClinicalTrials.gov ID
- NCT06533982
- Acronym / sponsor ID
- WOMEN-EX-MOD / WOMEN-EX-MOD
- Conditions
- Menopause, Blood Pressure, Cognitive Decline
- Keywords
- Physical exercise, High intensity interval exercise, Handgrip
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- University of PoitiersUniversity, hospital or other
- Study start
- 10 Mar 2023 (actual)
- Primary completion
- 28 Mar 2023 (actual)
- Study completion
- 20 Dec 2023 (actual)
- First posted
- 1 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Menopause is a natural stage in female aging, increasing cardiometabolic risk and making cardio-neuro-vascular disease (CNVD) the leading cause of mortality in women over 60. Declining ovarian hormones are linked to changes in body composition, increased blood pressure, and mild cognitive impairment. Menopause also often involves significant symptoms like menopausal vasomotor symptoms (VMS), affecting 60-80% of women for 5-10 years. Women with VMS exhibit a worse cardiovascular profile and greater cognitive decline.
Physical exercise is a promising non-pharmacological option to reduce CNVD risk and limit cognitive impairment in postmenopausal women, who have a 10-year window post-menopause during which physical activity benefits vascular and possibly neurovascular health. Studies link physical activity to lower cognitive decline and improved quality of life. However, optimal exercise modalities for managing CNVD risk in postmenopausal women remain undetermined.
Detailed description
Menopause is a natural stage in the female aging process, resulting in increased cardiometabolic risk, making cardio-neuro-vascular disease (CNVD) the leading cause of female mortality worldwide after the age of 60. Indeed, falling ovarian hormone concentrations are associated with altered body composition, increased blood pressure, as well as mild cognitive impairment.
For some women, menopause is also accompanied by symptoms that have a significant impact on their quality of life. Among these, menopausal vasomotor symptoms (VMS - hot flushes, night sweats...) are the most frequent, affecting 60% to 80% of women for an average of 5 to 10 years. Several studies have highlighted an altered cardiovascular profile (dyslipidemia, insulin resistance, pre-hypertension/hypertension...) and a more marked decline in cognitive performance in women with VMS.
In order to reduce the risk of CNVD and limit cognitive impairment, physical exercise appears to be a particularly interesting non-pharmacological management option for postmenopausal women. Indeed, the latter seem to present a 10-year post-menopausal time window, during which physical activity has a positive vascular and probably neurovascular effect, although the latter remains to be demonstrated. Numerous studies have also shown that physical activity is associated with a lower rate of cognitive decline, and improved quality of life.
However, to date, there is little evidence to determine which exercise modalities are most effective in managing the risk of CNVD in postmenopausal women.
The aims of this study:
- To examine the effect of exercise on markers of cardio-neuro-vascular health and cognition in postmenopausal women.
- Second, to compare the differences in the cardio-neuro-vascular and cognitive response to exercise, dependent on the type of exercise, the physical fitness and the presence of menopausal symptoms.
- Third, to examine the effect of menopausal symptoms, and physical fitness on cardio-neuro-vascular health markers and cognitive health markers.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| High intensity interval exercise session | Experimental | Other: High intensity interval exercise sessionPerformed on an ergometer, the intensity of the session is adapted to the participant's physical capacity, initially assessed by the VO2max test at baseline. The session begins with a 5-minute warm-up at 50% of maximum aerobic power (MAP). The exercise then consists of 2 sets of 12 repetitions of 15 seconds each at 100% of MAP and 15 seconds of passive recovery. 2-minute of passive recovery is recommended between the two sets. The session ends with 5-minute of recovery at 50% of MAP. |
| Isometric neuromuscular exercise session | Experimental | Other: Isometric neuromuscular exercise sessionPerformed with a handgrip (K-Force grip, KINVENT), the intensity of the session is adapted to the participant's capacity, initially assessed by the isometric maximal voluntary force (MVF) measurement at the beginning of the session. The session consists of 4 repetitions of 2 minutes at 30% of the isometric MVF, separated by 1 minute recovery. |
| Control session | No intervention | –Participants are seated for 30 minutes. |
Who may qualify
- Ages
- 45 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Menopausal women (absence of menstruation for 12 consecutive months) for less than 10 years
- Women with or without vasomotor symptoms
- Women covered by the French Social Security system
Key exclusion criteria (11 listed)
- Surgical menopause (oophorectomy)
- Premature ovarian failure
- Chronic renal failure
- Respiratory pathology (unstable asthma, respiratory insufficiency or pulmonary hypertension)
- Cardiovascular disease (coronary, valvular, hypertrophic, hypertensive, infiltrative, constrictive or rhythmic)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High intensity interval exercise sessionPhysical activity session supervised and adapted on ergometer | Other | High intensity interval exercise session |
| Isometric neuromuscular exercise sessionPhysical activity session supervised and adapted with a handgrip | Other | Isometric neuromuscular exercise session |
Primary outcome
Systolic and diastolic blood pressure (ambulatory blood pressure measurement)
Time frame: After sessions (24 hours)
Post-exercise hypotension, using the Mobil-O-Graph (mmHg).
Systolic and diastolic blood pressure (resting)
Time frame: Before and after sessions (15 minutes)
Automated oscillometric tensiometer (mmHg).
25 secondary outcomes
Concentration of cerebral oxygenation
Time frame: Before, during, and after sessions (1 hour)
Working memory
Time frame: Before and after sessions (10 minutes)
Episodic memory
Time frame: Before and after sessions (15 minutes)
Executive function
Time frame: Before and after sessions (15 minutes)
Perception of exertion
Time frame: After sessions (1 minute)
Endothelial function (brachial artery dilation capacity)
Time frame: Baseline (30 minutes)
Baroreflex sensitivity
Time frame: Baseline (1 hour)
Aortic systolic and diastolic blood pressure
Time frame: Baseline (15 minutes)
Arterial stiffness (pulse wave velocity)
Time frame: Baseline (15 minutes)
Physical fitness
Time frame: Baseline (30 minutes)
Blood lipid concentrations
Time frame: Baseline (5 minutes)
Blood hormone concentrations
Time frame: Baseline (5 minutes)
Body weight
Time frame: Baseline (1 minute)
Body composition
Time frame: Baseline (1 minute)
Height
Time frame: Baseline (1 minute)
Body mass index
Time frame: Baseline (1 minute)
Cognitive assessment
Time frame: Baseline (15 minutes)
Menopausal rating scale
Time frame: Baseline (15 minutes)
Hot flash related daily interference scale
Time frame: Baseline (15 minutes)
Hospital Anxiety and Depression Scale
Time frame: Baseline (15 minutes)
Global physical activity questionnaire
Time frame: Baseline (15 minutes)
Daily tobacco and alcohol use
Time frame: Baseline
Age
Time frame: Baseline
Educational level
Time frame: Baseline
Number of children
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2024.
- Background: PubMed 30683584Armas Rojas N, Dobell E, Lacey B, Varona-Perez P, Burrett JA, Lorenzo-Vazquez E, Calderon Martinez M, Sherliker P, Bess Constanten S, Morales Rigau JM, Hernandez Lopez OJ, Martinez Morales MA, Alonso Aloma I, Achiong Estupinan F, Diaz Gonzalez M, Rosquete Munoz N, Cendra Asencio M, Peto R, Emberson J, Duenas Herrera A, Lewington S. Burden of hypertension and associated risks for cardiovascular mortality in Cuba: a prospective cohort study. Lancet Public Health. 2019 Feb;4(2):e107-e115. doi: 10.1016/S2468-2667(18)30210-X. Epub 2019 Jan 23.
- Background: PubMed 30843880Greendale GA, Sternfeld B, Huang M, Han W, Karvonen-Gutierrez C, Ruppert K, Cauley JA, Finkelstein JS, Jiang SF, Karlamangla AS. Changes in body composition and weight during the menopause transition. JCI Insight. 2019 Mar 7;4(5):e124865. doi: 10.1172/jci.insight.124865. eCollection 2019 Mar 7.
- Background: PubMed 32910516Boyle CP, Raji CA, Erickson KI, Lopez OL, Becker JT, Gach HM, Kuller LH, Longstreth W Jr, Carmichael OT, Riedel BC, Thompson PM. Estrogen, brain structure, and cognition in postmenopausal women. Hum Brain Mapp. 2021 Jan;42(1):24-35. doi: 10.1002/hbm.25200. Epub 2020 Sep 10.
- Background: PubMed 25686030Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015 Apr;175(4):531-9. doi: 10.1001/jamainternmed.2014.8063.
- Background: PubMed 32585222Zhu D, Chung HF, Dobson AJ, Pandeya N, Anderson DJ, Kuh D, Hardy R, Brunner EJ, Avis NE, Gold EB, El Khoudary SR, Crawford SL, Mishra GD. Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies. Am J Obstet Gynecol. 2020 Dec;223(6):898.e1-898.e16. doi: 10.1016/j.ajog.2020.06.039. Epub 2020 Jun 23.
- Background: PubMed 31077368Gliemann L, Hellsten Y. The exercise timing hypothesis: can exercise training compensate for the reduction in blood vessel function after menopause if timed right? J Physiol. 2019 Oct;597(19):4915-4925. doi: 10.1113/JP277056. Epub 2019 Jun 30.
- Background: PubMed 25008420Anderson D, Seib C, Rasmussen L. Can physical activity prevent physical and cognitive decline in postmenopausal women? A systematic review of the literature. Maturitas. 2014 Sep;79(1):14-33. doi: 10.1016/j.maturitas.2014.06.010. Epub 2014 Jun 20.
- Background: PubMed 35964395Hybholt M. Psychological and social health outcomes of physical activity around menopause: A scoping review of research. Maturitas. 2022 Oct;164:88-97. doi: 10.1016/j.maturitas.2022.07.014. Epub 2022 Aug 3.
- Derived from this study: PubMed 41273313Bourvellec ML, Delpech N, Sosner P, Fritel X, Bosquet L, Enea C. Effect of Exercise Modalities on Post-Exercise Hypotension in Normotensive Postmenopausal Women: A Randomized Controlled Trial on Vasomotor Symptoms Influence. Eur J Sport Sci. 2025 Dec;25(12):e70091. doi: 10.1002/ejsc.70091.
- Individual participant dataSharing planned: No
Related trials for Menopause
Not yet recruitingPhase 3
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
Obesity
Not yet recruiting
A Clinical Trial to Evaluate the Effects of A Supplement on Symptoms of Menopause and Overall Well-being
Menopause, Menopausal Symptoms
Active, not recruitingObservational study
Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections
Urinary Tract Infections, Menopause
Recruiting
Hemodynamics After Resistance Training
Perimenopause
Not yet recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laurent Bosquet, Pr principal investigator
University of Poitiers - Faculty of Sport Science - MOVE Laboratory (UR20296)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High intensity interval exercise session and Isometric neuromuscular exercise session in people with Menopause and Blood Pressure, run by University of Poitiers at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systolic and diastolic blood pressure (ambulatory blood pressure measurement) (time frame: After sessions (24 hours)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06533982, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2024.